@entity11833 and @entity4736 as a predictive parameter for XXXX treated with @entity900 and/or @entity136 .

@entity1 @entity43 @entity4736 @entity11833 @entity788 @entity5 @entity900 @entity2 @entity136
BACKGROUND: We aimed to investigate the impact of @entity4736 and @entity11833 expression on response to @entity900 and/or @entity136 chemotherapy in @entity1 with @entity43 . MATERIAL AND METHODS: @entity1 with @entity43 , who used @entity900 and/or @entity136 therapy were included; hospital files were examined and @entity4736 and @entity11833 expression were evaluated with an immunohistochemical method on tissue cross sections from paraffin blocks of the @entity5 . RESULTS: Out of 89 @entity1 , 51%, 30% and 19% had @entity43 , respectively. The response rates to the therapy in @entity1 with lung and @entity43 having low @entity11833 expression were 62% and 90%, respectively (p = 0.028 and p = 0.044, respectively). No significant association was found between @entity11833 expression and response to therapy in @entity1 with @entity788 (p = 0.354). Therapeutic response rates in @entity1 with lung and @entity788 with low @entity4736 expression were 60% and 82%, respectively. Survival rates were higher in @entity1 with @entity2 in which @entity11833 and @entity4736 expressions were low. Median survival duration in @entity1 with @entity43 showing low @entity11833 and @entity4736 expressions was longer than that seen in @entity1 with high expressions. Although no significant correlation was found between @entity11833 and the survival in @entity43 (p = 0.183), there was a significant correlation between @entity4736 expression and survival in @entity1 with @entity788 (p = 0.005). CONCLUSIONS: Our results suggest a predictive value of @entity11833 in lung and @entity43 , and also @entity4736 in lung and @entity788 .
